Auspex Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people with movement disorders and other rare diseases, including orphan diseases. Its pipeline includes product candidates to address unmet medical needs in hyperkinetic movement disorders, such as chorea (abnormal involuntary movements) associated with Huntington's disease, an orphan disease, tardive dyskinesia and Tourette syndrome in the pediatric population, which is an orphan disease, as well as other orphan indications. Its lead product candidate is SD-809, which is a small molecule inhibitor of vesicular monoamine transporter 2 (VMAT2). Its other programs include SD-560, SD-1077 and SD-254.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: NASDAQ:ASPX
- CUSIP: N/A
- Web: N/A
- 50 Day Moving Avg: $94.00
- 200 Day Moving Avg: $59.00
- 52 Week Range: $15.00 - $101.00
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -50.50
- P/E Growth: 0
- Average Volume: 634,233 shs.
Frequently Asked Questions for Auspex Pharmaceuticals (NASDAQ:ASPX)
What is Auspex Pharmaceuticals' stock symbol?
Auspex Pharmaceuticals trades on the NASDAQ under the ticker symbol "ASPX."
How were Auspex Pharmaceuticals' earnings last quarter?
Auspex Pharmaceuticals Inc (NASDAQ:ASPX) released its quarterly earnings results on Monday, March, 16th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.59) by $0.15. View Auspex Pharmaceuticals' Earnings History.
Who are some of Auspex Pharmaceuticals' key competitors?
Some companies that are related to Auspex Pharmaceuticals include Orange Belgium (MBSRF), Abengoa SA (ABGB), Apple (AAPL), Alphabet (GOOGL), Alphabet (GOOG), Microsoft (MSFT), Amazon.com (AMZN), Premier Foods Spon (PRRFY), Facebook (FB), Berkshire Hathaway (BRK-A), Nestle SA (NSRGY), Roche Holding (RHHBY), RDS-A (RDS-A), Comcast (CMCSA), Intel (INTC), Cisco Systems (CSCO), LVMH Moet Hennessy Louis Vuitton SE (LVMUY) and Inditex (IDEXY).
How do I buy Auspex Pharmaceuticals stock?
Shares of Auspex Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Auspex Pharmaceuticals stock cost?
One share of Auspex Pharmaceuticals stock can currently be purchased for approximately $101.00.
Consensus Ratings for Auspex Pharmaceuticals (NASDAQ:ASPX) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Auspex Pharmaceuticals (NASDAQ:ASPX)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Auspex Pharmaceuticals (NASDAQ:ASPX)Earnings History by Quarter for Auspex Pharmaceuticals (NASDAQ:ASPX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Auspex Pharmaceuticals (NASDAQ:ASPX)
Current Year EPS Consensus Estimate: $-4 EPS
Next Year EPS Consensus Estimate: $-2 EPS
Dividend History for Auspex Pharmaceuticals (NASDAQ:ASPX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Auspex Pharmaceuticals (NASDAQ:ASPX)Insider Trades by Quarter for Auspex Pharmaceuticals (NASDAQ:ASPX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/16/2015||David A Stamler||Insider||Sell||3,000||$80.00||$240,000.00|| |
|2/13/2015||Ventures Vii Lp Cmea||Major Shareholder||Sell||122,667||$63.08||$7,737,834.36|| |
|2/11/2015||Ventures Vii Lp Cmea||Major Shareholder||Sell||84,154||$61.06||$5,138,443.24|| |
|2/6/2015||Ventures Vii Lp Cmea||Major Shareholder||Sell||93,179||$59.39||$5,533,900.81|| |
|1/28/2015||Alex Zisson||Director||Sell||730,000||$53.11||$38,770,300.00|| |
|1/28/2015||James E Flynn||Insider||Buy||1,500,000||$56.50||$84,750,000.00|| |
|1/28/2015||Panorama Capital, L.P.||Major Shareholder||Sell||270,000||$53.11||$14,339,700.00|| |
|12/22/2014||David A Stamler||Insider||Sell||2,660||$53.55||$142,443.00|| |
|12/18/2014||Ventures Vii Lp Cmea||Major Shareholder||Sell||195,000||$50.14||$9,777,300.00|| |
|10/30/2014||Ventures Vii Lp Cmea||Major Shareholder||Sell||19,000||$27.15||$515,850.00|| |
|10/28/2014||Ventures Vii Lp Cmea||Major Shareholder||Sell||14,500||$27.02||$391,790.00|| |
|10/27/2014||Ventures Vii Lp Cmea||Major Shareholder||Sell||3,413||$27.11||$92,526.43|| |
|10/24/2014||Ventures Vii Lp Cmea||Major Shareholder||Sell||16,500||$26.97||$445,005.00|| |
|10/6/2014||Ventures Vii Lp Cmea||Major Shareholder||Sell||7,109||$23.45||$166,706.05|| |
|9/19/2014||Gerald T Proehl||Director||Buy||1,466||$21.75||$31,885.50|| |
|9/5/2014||Ventures Vii Lp Cmea||Major Shareholder||Sell||25,600||$23.86||$610,816.00|| |
|9/3/2014||Ventures Vii Lp Cmea||Major Shareholder||Sell||22,700||$23.08||$523,916.00|| |
|8/28/2014||Ventures Vii Lp Cmea||Major Shareholder||Sell||29,600||$22.03||$652,088.00|| |
|8/26/2014||Ventures Vii Lp Cmea||Major Shareholder||Sell||6,300||$21.35||$134,505.00|| |
|8/22/2014||Ventures Vii Lp Cmea||Major Shareholder||Sell||1,700||$20.56||$34,952.00|| |
|7/16/2014||R Scott Greer||Director||Buy||5,190||$19.25||$99,907.50|| |
|2/10/2014||James E Flynn||Insider||Buy||700,000||$12.00||$8,400,000.00|| |
|2/10/2014||Panorama Capital, L.P.||Major Shareholder||Buy||333,334||$12.00||$4,000,008.00|| |
|2/10/2014||Pratik Shah||CEO||Buy||8,333||$12.00||$99,996.00|| |
|2/10/2014||Sepehr Sarshar||Director||Buy||67,263||$12.00||$807,156.00|| |
Headline Trends for Auspex Pharmaceuticals (NASDAQ:ASPX)
Latest Headlines for Auspex Pharmaceuticals (NASDAQ:ASPX)
Auspex Pharmaceuticals (ASPX) Chart for Thursday, May, 25, 2017